Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 18 results found. Search for [ emergency use approval AstraZeneca-Oxford's COVID-19 vaccine ]

Results 1 to 18 of 18
BusinessToday.In
February 16, 2021
Astrazeneca Pharma India share opened with a gain of 3.26% at Rs 3,700 today. On NSE, the share rose 11.50% to Rs 4,050 against previous close of Rs 3,630.75


BusinessToday.In
February 16, 2021
Stock Market Updates Today: Sun Pharma, ITC, HDFC were trading among the top losers today while RIL, L&T, Maruti were among the top gainers


Chitranjan Kumar
February 15, 2021
COVID-19 vaccine: The AstraZeneca-Oxford product is a viral vectored vaccine called ChAdOx1-S [recombinant], which is being produced at several manufacturing sites, as well as in the Republic of Korea and India


BusinessToday.In
January 2, 2021
Experts will review the indigenously developed vaccine a day after the Subject Expert Committee (SEC) had recommended Serum-Oxford's Covishield COVID-19 vaccine to the Drugs Controller General of India (DCGI) for emergency use authorisation


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


BusinessToday.In
January 1, 2021
CDSCO's expert panel has recommended the Serum Institute of India's Covishield COVID-19 vaccine for emergency use authorisation to DCGI


BusinessToday.In
January 1, 2021
Reports suggest that an expert panel will meet to take up the application for emergency use of the three vaccines


BusinessToday.In
December 30, 2020
Gagandeep Kang said although the Centre has planned to vaccinate 30 crore Indians against the COVID-19, it will be in 2022, that two-third of the population will get vaccinated


BusinessToday.In
December 23, 2020
DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data


BusinessToday.In
December 6, 2020
\"During this pandemic phase, Pfizer will supply this vaccine only via government contracts based on agreements with respective govt authorities & following regulatory authorization or approval\", the US pharma firm said


BusinessToday.In
December 6, 2020
Pfizer Inc submitted application to DCGI seeking emergency use authorisation on Dec 4; also seeks permission to import vaccine for sale and distribution in India


BusinessToday.In
December 5, 2020
Confirmation of approval by National Health Regulatory Authority of Bahrain followed thorough analysis and review undertaken by authority of all available data


BusinessToday.In
November 23, 2020
It has been found that one of the vaccine's dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply, says AstraZeneca


BusinessToday.In
November 23, 2020
Coronavirus vaccine update: Adar Poonawalla, the CEO of Serum Institute had recently said that his company might sell a two-shot COVID-19 vaccine for around Rs 500-600 for the general public


BusinessToday.In
November 20, 2020
Adar Poonawalla said if things go according to the plan, the coronavirus vaccine will be available for vulnerable populations by January or February. And, in March or April, the vaccine will enter the market for the general public


BusinessToday.In
October 1, 2020
Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites


BusinessToday.In
August 29, 2020
COVID-19 vaccine update: The expert group of the committee, headed by Dr. VK Paul, is also in contact with domestic as well as multinational vaccine makers to understand how soon a COVID-19 vaccine will be ready


BusinessToday.In
July 22, 2020
Coronavirus (COVID-19) Vaccine News Latest Updates: Dr Cyrus Poonawalla, Chairman of the Poonawalla Group, says a just a few million doses of the potential COVID-19 vaccine will not be enough and the company intends to manufacture around 1 billion doses after getting all the necessary approvals


PAGES 1 OF 1